Ignite Creation Date:
2025-12-25 @ 1:06 AM
Ignite Modification Date:
2026-01-01 @ 5:18 AM
Study NCT ID:
NCT00678093
Status:
COMPLETED
Last Update Posted:
2008-05-15
First Post:
2008-05-08
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Effects of a Mulligan Mobilisation in the Lumbar Flexion Range of Asymptomatic Subjects
Sponsor:
University of Manchester
Organization:
Study Overview
Official Title:
The Effects of the Mulligan Mobilisation Sustained Natural Apophyseal Glide (SNAG) in the Lumbar Flexion Range of Asymptomatic Subjects as Measured by the Zebris CMS20 3-D Motion Analysis System
Status:
COMPLETED
Status Verified Date:
2008-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
Mulligan
Brief Summary:
Mulligan's mobilisation techniques are believed to increase the range of movement (ROM) in patients with low back pain. The primary aim of this study was to investigate the mechanical effects of Mulligan's "SNAG" technique on lumbar flexion ROM. The secondary aim was to measure the intra- and inter-day reliability of lumbar ROM employing the same procedure, and utilising a 3-D motion analysis system for measuring range of motion (ROM).
Detailed Description:
The primary aim of this study was to investigate the mechanical effects of Mulligan's "SNAG" technique on lumbar flexion ROM. The secondary aim was to measure the intra- and inter-day reliability of lumbar ROM employing the same procedure. For the interventional component of the study, 49 asymptomatic volunteers participated in it. Subjects were randomly assigned into either a treatment (SNAG) group (n=25), or a placebo (SHAM) group (n=24). The "SNAG" technique was applied on L3 and L4 spinal levels by an experienced manual therapist. SNAGs were performed with active flexion in sitting, 10 times at each level. The placebo-SHAM was similar to the SNAG without however applying the appropriate direction or force. Lumbar ROM was measured by a three dimensional electronic goniometer (Zebris CM20), before and after each technique. For the reliability component, five measurements in two different days (one week apart) were performed in 20 healthy subjects.
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: